Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - COLLEGIUM PHARMACEUTICAL, INC | coll-20171231ex32232a79c.htm |
| EX-32.1 - EX-32.1 - COLLEGIUM PHARMACEUTICAL, INC | coll-20171231ex3219106ae.htm |
| EX-31.2 - EX-31.2 - COLLEGIUM PHARMACEUTICAL, INC | coll-20171231ex312feffb3.htm |
| EX-31.1 - EX-31.1 - COLLEGIUM PHARMACEUTICAL, INC | coll-20171231ex311906fa7.htm |
| EX-23.2 - EX-23.2 - COLLEGIUM PHARMACEUTICAL, INC | coll-20171231ex2322d0cdd.htm |
| EX-21.1 - EX-21.1 - COLLEGIUM PHARMACEUTICAL, INC | coll-20171231ex2116c8196.htm |
| EX-10.28 - EX-10.28 - COLLEGIUM PHARMACEUTICAL, INC | coll-20171231ex10286fe23.htm |
| EX-10.27 - EX-10.27 - COLLEGIUM PHARMACEUTICAL, INC | coll-20171231ex1027d09a8.htm |
| 10-K - 10-K - COLLEGIUM PHARMACEUTICAL, INC | coll-20171231x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-213964 on Form S-3 and Registration Statement Nos. 333-207744 and 333-218767 on Form S-8 of our report dated March 7, 2018, relating to the consolidated financial statements of Collegium Pharmaceutical, Inc. and subsidiaries, appearing in this Annual Report on Form 10-K of Collegium Pharmaceutical, Inc. for the year ended December 31, 2017.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 7, 2018